Allarity Therapeutics Holds Annual Stockholders Meeting

Allarity Therapeutics ( (ALLR) ) just unveiled an announcement.

On June 13, 2025, Allarity Therapeutics held its annual stockholders meeting where five proposals were voted on. While most proposals were approved, the 2021 Plan Amendment and Officer Exculpation Amendment proposals did not pass. The meeting saw participation from 41% of the company’s shareholders, ensuring a quorum. The election of Thomas H. Jensen as a Class III director and the ratification of Wolf & Company, P.C. as the independent auditor were among the approved proposals, indicating a continued strategic direction for the company.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

To see Spark’s full report on ALLR stock, click here.

More about Allarity Therapeutics

Allarity Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing novel oncology therapeutics. The company is engaged in advancing its pipeline of targeted cancer treatments to address unmet medical needs.

Average Trading Volume: 1,146,739

Technical Sentiment Signal: Sell

Current Market Cap: $12.58M

Find detailed analytics on ALLR stock on TipRanks’ Stock Analysis page.